BCMA x CD3 drugs for Multiple Myeloma
11 tracked BCMA x CD3 drugs in the Multiple Myeloma race. The class explanation lives on the BCMA x CD3 page; the full indication pipeline across every mechanism is on the Multiple Myeloma page.
3 approved / phase 46 Phase 31 Phase 21 Phase 1/2
Head-to-head evidence: Elranatamab vs Etentamig · Elranatamab vs F182112 · Elranatamab vs Gamgertamig (CM336) · Elranatamab vs Linvoseltamab · Elranatamab vs TQB2934 · Elranatamab vs Teclistamab